Table 2.
Effects of intranasal natural products on weight.
| Author, year | Modeling Method(Virus type, Dose) | Intervention | Lowest bodyweight point | Last observation time point | P | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nature | Administration | Dose | T | M | T | M | |||||||
| Days | Body weight |
Days | Body weight |
Days | Body weight |
Days | Body weight |
||||||
| Hayashi 2007 (29) | H1N1 PR8, 4LD50 | Cinnamalde-hyde (CA) | Intranasal inoculation | 250 μg | 7 | 114.6%#+ | 10 | 83.2%# | 10 | 116.8%#+ | △ | <0.05 | |
| Inhalation via natural volatilization | 50 mg/cage (5 mice/cage) | 10 | 110.1%#+ | △ | |||||||||
| Theisen 2012 (21) |
H1N1 PR8, 4LD50 | EPs® 7630 | Inhalation chamber connected to aerosol nebulizers | 5 mg/ml (10 min) | 8 | 78.7%# | 7 | 75.8%# | 14 | 93.1%# | △ | / | |
| Haasbach 2014 (34) | H1N1 RB1, 5LD50 | Ladania067 | Aerosol inhalation | 300 mg/6 ml | 6 | 75.1%# | 7 | 69.7%# | 10 | 77.8%# | △ | / | |
| Kim 2015 (35) |
H1N1 PR8, 1LD50 | Poly-gamma glutamate (γ-PGA) | Intranasal administration | 100 μg | 8 | 82.8%# | 8 | 77.8%# | 14 | 100.8%# | 14 | 98.0%# | / |
| H1N1 CA04, 1LD50 | 8 | 82.2%# | 8 | 81.7%# | 14 | 102.4%# | 14 | 93.2%# | |||||
| Qiu 2021 (26) |
H9N2 A/Chicken/Guangdong/1996, 2LD50 | Shuanghuanglian | Aerosol inhalation | 300 mg/mL, 0.5 mL/min (60 min) | 5 | 90.9% | 5 | 87.4% | △ | △ | >0.05 | ||
| Joo 2022(1) (36) | H1N1 A/Californ ia/07/2009 and H1N1 PR8, 10³ pfu | Elaeocarpus sylvestris Extract (ESE) | Intranasal administration | 0.5 mg/kg | 8 | 79.2%# | 8 | 72.8%# | 14 | 97.2%# | △ | <0.05 | |
| 1,2,3,4,6-penta-O-galloyl- β-D-glucose (PGG) |
12 | 84.4%# | 14 | 85.3%# | <0.05 | ||||||||
| Geraniin (GE) | 9 | 81.3%# | 14 | 101.2%# | <0.001 | ||||||||
| Yang 2022 (19) | H1N1 PR8, 3LD50 | D-limonene | Intranasal inoculation | 10 mg/kg | 6 | 72.0%# | 8 | 65.4%# | 21 | 102.3%# | △ | / | |
| 30 mg/kg | 6 | 74.8%# | 21 | 101.6%# | |||||||||
| L-limonene | 125 mg/kg | 8 | 73.7%# | 8 | 69.8%# | 21 | 110.1%# | 21 | 107.6%# | ||||
| 250 mg/kg | 8 | 78.5%# | 21 | 108.9%# | |||||||||
| Mega 2024 (39) | H3N2 A virus X31, 10³ PFU |
Enriched seaweed extract | Intranasal administration | 5 mg/kg | 4 | 91.6% | 4 | 91.3% | 5 | 94.5% | 5 | 92.7% | >0.05 |
#Data sourced from Origin 2024.
+Data compared with the control group of this study on the same day.
△Same as the data measured at the lowest point.
/P was no mentioned.